Belite Bio (BLTE) Amortization (2024 - 2025)

Belite Bio (BLTE) recorded quarterly Amortization of $1593.0 in Q3 2025, up 18.09% quarter-over-quarter from $1349.0 in Q4 2024.

Belite Bio (BLTE) Amortization (2024 - 2025) Analysis & Trends

Belite Bio's Amortization history runs 2 years deep, the most recent figure standing at $1593.0 for Q3 2025.

  • In Q3 2025, Amortization changed N/A year-over-year to $1593.0; the TTM figure through Sep 2025 stood at $1593.0 (changed N/A YoY), while the FY2024 annual figure was $1349.0, changed N/A from the prior year.
  • Amortization was $1593.0 for Q3 2025 at Belite Bio, up from $1349.0 in the prior quarter.
  • In the past five years, Amortization ranged from a high of $1593.0 in Q3 2025 to a low of $1349.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -13.75 Mn
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Regeneron Pharmaceuticals 66.09 Bn 57.33 Bn 3.31 Bn -

Historic Data

Download Data
DateValue
Sep 30, 2025 1,593.00
Sep 30, 2025 1,593.00
Dec 31, 2024 1,349.00
Dec 31, 2024 1,349.00